A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
A phase 3 trial of Abemaciclib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by Eli Lilly and Company, active and no longer recruiting.
Overview
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer is a phase 3 interventional study registered as NCT02107703 by Eli Lilly and Company, with 669 participants enrolled, started 2014-07-22 and due to reach its primary completion in 2017-02-14. Interventions recorded: Abemaciclib, Fulvestrant and Placebo. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialA Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Shares Abemaciclib, Fulvestrant, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Shares Abemaciclib, Fulvestrant and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialComparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialCAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.